The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Clinical Effectiveness and Cost-effectiveness of Screening for Anal Squamous Intraepithelial Lesions in Homosexual and Bisexual HIV-Positive Men
Abstract
CONTEXT: Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus-related anal neoplasia and anal squamous cell carcinoma (SCC). OBJECTIVE: To estimate the clinical benefits and cost-effectiveness of screening HIV-positive homosexual and bisexual men foranal squamous intraepithelial lesions (ASIL) and anal SCC. DESIGN: Cost-effectiveness analysis performed from a societal perspective that used reference case recommendations from the Panel on Cost-Effectiveness in Health and Medicine. A state-transition Markov model was developed to calculate lifetime costs, life expectancy, and quality-adjusted life expectancy for no screening vs several screening strategies for ASIL and anal SCC using anal Papanicolaou (Pap) testing at different intervals. Values for incidence, progression, and regression of anal neoplasia; efficacy of screening and treatment; natural history of HIV; health-related quality of life; and costs were obtained from the literature. SETTING AND PARTICIPANTS: Hypothetical cohort of homosexual and bisexual HIV-positive men living in the United States. MAIN OUTCOME MEASURES: Life expectancy, quality-adjusted life expectancy, quality-adjusted years of life saved, lifetime costs, and incremental cost-effectiveness ratio. RESULTS: Screening for ASIL increased quality-adjusted life expectancy at all stages of HIV disease. Screening with anal Pap tests every 2 years, beginning in early HIV disease (CD4 cell count >0.50 x 10(9)/L), resulted in a 2.7-month gain in quality-adjusted life expectancy for an incremental cost-effectiveness ratio of $13,000 per quality-adjusted life year saved. Screening with anal Pap tests yearly provided additional benefit at an incremental cost of $16,600 per quality-adjusted life year saved. If screening was not initiated until later in the course of HIV disease (CD4 cell count <0.50 x 10(9)/L), then yearly Pap test screening was preferred due to the greater amount of prevalent anal disease (cost-effectiveness ratio of less than $25,000 per quality-adjusted life year saved compared with no screening). Screening every 6 months provided little additional benefit over that of yearly screening. Results were most sensitive to the rate of progression of ASIL to anal SCC and the effectiveness of treatment of precancerous lesions. CONCLUSIONS: Screening HIV-positive homosexual and bisexual men for ASIL and anal SCC with anal Pap tests offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Abstract of the United States
(2005) · Encyclopedia of Statistical Sciences · doi:10.1002/0471667196.ess2527 · Cited by 8,785
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Spectrum of AIDS-associated malignant disorders
Goedert, J. J., Coté, T. R., Virgo, P., Scoppa, S. M., Kingma, D. W., Gail, M. H., Jaffe, E. S., & Biggar, R. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09028-4 · Cited by 701
Sexual Practices, Sexually Transmitted Diseases, and the Incidence of Anal Cancer
Daling, J. R., Weiss, N. S., Hislop, T. G., Maden, C., Coates, R. J., Sherman, K. J., Ashley, R. L., Beagrie, M., Ryan, J. A., & Corey, L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710153171601 · Cited by 665
Palefsky, J. M., Holly, E. A., Ralston, M. L., & Jay, N. (1998) · The Journal of Infectious Diseases · doi:10.1086/514194 · Cited by 543
Interim Guidelines for Management of Abnormal Cervical Cytology
Kurman, R. J. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510470070037 · Cited by 530
Palefsky, J. M., Holly, E. A., Ralston, M. L., Jay, N., Berry, J. M., & Darragh, T. M. (1998) · AIDS · doi:10.1097/00002030-199805000-00011 · Cited by 391
Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care
Taplin, S. H., Barlow, W., Urban, N., Mandelson, M. T., Timlin, D. J., Ichikawa, L., & Nefcy, P. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.6.417 · Cited by 344
Anal Cytology as a Screening Tool for Anal Squamous Intraepithelial Lesions
Palefsky, J. M., Holly, E. A., Hogeboom, C. J., Berry, J. M., Jay, N., & Darragh, T. M. (1997) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199704150-00004 · Cited by 343
Palefsky, J. M., Holly, E. A., Hogeboom, C. J., Ralston, M. L., DaCosta, M. M., Botts, R., Berry, J. M., Jay, N., & Darragh, T. M. (1998) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199804010-00004 · Cited by 306
Statistical analysis of the stages of HIV infection using a Markov model
Longini, I. M., Clark, W. S., Byers, R. H., Ward, J. W., Darrow, W. W., Lemp, G. F., & Hethcote, H. W. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080708 · Cited by 304
Resource-based relative values. An overview
Hsiao, W. C. (1988) · JAMA · doi:10.1001/jama.260.16.2347 · Cited by 287
Colposcopic appearance of anal squamous intraepithelial lesions: Relationship to histopathology
Jay, N., Berry, M. J., Hogeboom, C. J., Holly, E. A., Darragh, T. M., & Palefsky, J. M. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02051199 · Cited by 265
Anal Cancer Incidence: Genital Warts, Anal Fissure or Fistula, Hemorrhoids, and Smoking
Holly, E. A., Whittemore, A. S., Aston, D. A., Ahn, D. K., Nickoloff, B. J., & Kristiansen, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.22.1726 · Cited by 262
The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg, K. A. (1998) · JAMA · doi:10.1001/jama.279.2.130 · Cited by 243
The Lifetime Cost of Treating a Person With HIV
Hellinger, F. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510040078033 · Cited by 240
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif, W. A., et al. (1998) · JAMA · doi:10.1001/jama.280.1.35 · Cited by 234
Changing Patterns of Anal Cancer Incidence in the United States, 1940‐1989
Melbye, M., Rabkin, C., Frisch, M., & Biggar, R. J. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117073 · Cited by 184
Molecular virology and epidemiology of human papillomavirus and cervical cancer.
Palefsky, J. M., & Holly, E. A. (1995) · PubMed · Cited by 153
Health Values of Patients Infected with Human Immunodeficiency Virus
Tsevat, J., SOLZAN, J. G., Kuntz, K. M., Ragland, J., Currier, J. S., Sell, R. L., & Weinstein, M. C. (1996) · Medical Care · doi:10.1097/00005650-199601000-00004 · Cited by 121
The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach.
Longini, I. M., Ws, C., Gardner, L. I., & Jf, B. (1991) · PubMed · Cited by 116
Survival from early, intermediate, and late stages of HIV infection.
Enger, C. L., Graham, N. M. H., Peng, Y. W., et al. (1996) · PubMed · Cited by 103
Increased Incidence of Cancer among Homosexual Men, New York City and San Francisco, 1978-1990
Koblin, B. A., Hessol, N. A., Zauber, A. G., Taylor, P. E., Buchbinder, S., Katz, M. H., & Stevens, C. E. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008861 · Cited by 102
Palefsky, J. M., Holly, E. A., Gonzales, J., Lamborn, K. R., & Hollander, H. (1992) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-199212000-00009 · Cited by 82
Human papillomavirus-associated malignancies in HIV-positive men and women
Palefsky, J. M. (1995) · Current Opinion in Oncology · doi:10.1097/00001622-199509000-00009 · Cited by 45
Northfelt, D. W., Swift, P. S., & Palefsky, J. M. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70392-0 · Cited by 44
Sonnex, C., Scholefield, J. H., Kocjan, G., Kelly, G., Whatrup, C., Mindel, A., & Northover, J. M. A. (1991) · Sexually Transmitted Infections · doi:10.1136/sti.67.1.21 · Cited by 35
Cited by
(2012) · Choice Reviews Online · doi:10.5860/choice.49-2699 · Cited by 2,593
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
Development of WHO guidelines on generalized cost-effectiveness analysis
Murray, C. J. L., Evans, D. B., Acharya, A., & Baltussen, R. M. P. M. (2000) · Health Economics · doi:10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o · Cited by 577
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg, M. J., Lau, B., Justice, A. C., Engels, E., Gill, M. J., Goedert, J. J., Kirk, G. D., D'Souza, G., Bosch, R. J., Brooks, J. T., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1012 · Cited by 520
Metadata
- Authors
- Goldie, S. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-05-19
- Volume
- 281
- Issue
- 19
- Pages
- 1822
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2147675930
- Cited by
- 419
- References
- 30
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.